

**Financial results for the year
ended March 31, 2014**

< Supplement >

May 9, 2014

 **SHIONOGI & CO., LTD.**

Contents

- 1 Financial results and forecast
- 2 Sales of main merchandise and finished goods
- 3 Management index
- 4 Capital investments and depreciation cost
- 5 R&D expenses
- 6 Employees
- 7 Consolidated statement of income
- 8 Consolidated balance sheets
- 9 Quarterly trend for FY2012 and FY2013
- 10 Consolidated affiliated companies and affiliated company accounted for by the equity method
- 11 Pipeline (as of May 2014)

1. Financial results and forecast

(billions of yen)

	FY2012 Results *	FY2013 Results	FY2014 Forecast	Change		FY2014 1H Forecast
				FY2013	FY2014	
Net Sales	282.9	289.7	269.0	6.8	(20.7)	130.0
<i>change %</i>	5.8	2.4	(7.2)			(6.3)
Operating Income	59.6	63.6	45.0	4.0	(18.6)	18.5
<i>change %</i>	-	6.7	(29.2)			(35.0)
Ordinary Income	58.9	63.9	50.0	5.0	(13.9)	24.0
<i>change %</i>	27.8	8.5	(21.8)			(13.8)
Net Income	66.7	41.8	33.0	(24.9)	(8.8)	16.0
<i>change %</i>	146.2	(37.3)	(21.1)			(25.3)

Note: Change % shows changes from the same period of the previous fiscal year

* Because of changing fiscal term, FY2012 results of Taiwan Shionogi & Co., Ltd. includes 15-month results from January 2012 to March 2013.

The Company has changed its presentation method for litigation expenses from FY2013.

Operating income for FY2012 has been restated to reflect this change.

However, the Y on Y change % has been omitted because it has not been calculated.

2. Sales of main merchandise and finished goods

(billions of yen)

	FY2012 Results	FY2013 Results	FY2014 Forecast	Change		FY2014 1H Forecast
				FY2013	FY2014	
Prescription drugs	165.7	168.3	167.0	2.6	(1.3)	80.5
<i>change %</i>	0.8	1.5	(0.8)			(0.5)
CRESTOR	38.1	41.1	42.5	3.0	1.4	21.0
IRBETAN Franchise	10.7	13.9	15.9	3.2	2.0	7.3
CYMBALTA	9.7	11.4	13.6	1.7	2.2	6.2
Total of 3 key products	58.5	66.3	72.0	7.8	5.7	34.5
OXYCONTIN Franchise	10.2	10.6	10.7	0.4	0.1	5.5
FINIBAX	5.0	4.7	4.6	(0.3)	(0.1)	2.3
DIFFERIN	4.0	4.4	4.6	0.4	0.2	2.1
PIRESPA	4.5	4.8	5.6	0.3	0.8	2.7
RAPIACTA	2.0	2.0	2.5	0.0	0.5	0.2
Total of 8 strategic products	84.2	92.9	100.0	8.7	7.1	47.3
FLOMOX	18.0	15.8	13.0	(2.2)	(2.8)	6.2
RINDERON	8.9	8.8	8.4	(0.1)	(0.4)	4.5
CLARITIN	6.3	4.9	4.1	(1.4)	(0.8)	1.7
FLUMARIN	6.0	5.4	4.4	(0.6)	(1.0)	2.3
Export/Overseas subsidiaries	*1 30.6	34.0	31.3	3.4	(2.7)	15.0
<i>change %</i>	80.3	11.1	(8.0)			(2.3)
Shionogi Inc.	17.0	21.4	17.7	4.4	(3.7)	7.9
Osphena	-	1.1	7.0	1.1	5.9	2.5
C&O	5.8	5.9	7.5	0.1	1.6	3.4
Contract manufacturing	7.3	8.4	11.4	1.1	3.0	4.8
<i>change %</i>	(4.6)	15.5	36.1			(4.2)
OTC and quasi-drugs	5.2	4.5	4.6	(0.7)	0.1	2.4
<i>change %</i>	2.8	(12.6)	1.9			3.4
Diagnostics	2.2	2.0	*2 -	(0.2)	-	*2 -
<i>change %</i>	(18.4)	(9.0)	-			-
Royalty income	69.8	70.7	52.0	0.9	(18.7)	26.0
<i>change %</i>	1.7	1.2	(26.4)			(22.2)
CRESTOR	63.0	65.7	47.5	2.7	(18.2)	24.2
Others	2.1	1.8	2.7	(0.3)	0.9	1.3
<i>change %</i>	7.8	(12.7)	(29.2)			(24.3)
Total	282.9	289.7	269.0	6.8	(20.7)	130.0
<i>change %</i>	5.8	2.4	(7.2)			(6.3)

Note: Change % shows changes from the same period of the previous fiscal year

Sales of each main merchandise and finished goods are shown on non-consolidated basis

* 1. Because of changing fiscal term, FY2012 results of Taiwan Shionogi & Co., Ltd. includes 15-month sales from January 2012 to March 2013.

* 2. From FY2014, "Diagnostics" is included in the "Others" item.

3. Management index

(Management index trend)

		FY2011	FY2012	FY2013
Ratio of operating income to net sales	%	17.6	21.1	21.9
Ratio of ordinary income to net sales	%	17.2	20.8	22.1
Ratio of net income to net sales	%	10.1	23.6	14.4
Total asset turnover		0.51	0.52	0.50
Equity ratio	%	65.9	73.1	80.1
Return on asset (ROA)	%	8.8	10.7	11.0
Return on equity (ROE)	%	8.1	17.5	9.4
Dividend payout ratio	%	49.4	21.1	36.8
Dividends on Equity (DOE)	%	4.0	3.7	3.5
Earnings per share	yen	80.93	199.25	124.91
Earnings per share (diluted)	yen	80.91	199.17	124.85

*The Company has changed its presentation method for litigation expenses from FY2013.
Ratio of operating income to net sales for FY2012 has been restated to reflect this change.*

4. Capital investments and depreciation cost

(billions of yen)

	FY2012 Results	FY2013 Results	FY2014 Forecast	Change		FY2014 1H Forecast
				FY2013	FY2014	
Investment in equipments	11.4	9.0	11.5	(2.4)	2.5	6.9
Depreciation cost	11.9	12.9	12.9	1.0	0.0	6.3
Amortization of goodwill	3.2	2.7	2.7	(0.5)	0.0	1.4

5. R&D expenses

(billions of yen)

	FY2012 Results	FY2013 Results	FY2014 Forecast	Change		FY2014 1H Forecast
				FY2013	FY2014	
R&D expenses	53.0	51.9	52.0	(1.1)	0.1	27.0
<i>change %</i>	<i>(1.1)</i>	<i>(2.1)</i>	<i>0.1</i>			5.5
% to net sales	18.7	17.9	19.3			20.8

Note: Change % shows changes from the same period of the previous fiscal year

6. Employees

	FY2012 Results	FY2013 Results	FY2014 Forecast	Change		FY2014 1H Forecast
				FY2013	FY2014	
Employees	6,082	6,165	6,220	83	55	6,270

7. Consolidated statement of income

(Unites: Million yen)

	FY2012 Results	FY2013 Results	Change	
Net sales	282,903	289,717	6,814	Increase in: Shionogi Inc.: 4.4 billion yen Shionogi: 2.5 billion yen
Cost of sales	78,574	77,993	(581)	
Gross profit	204,329	211,724	7,395	
Selling, general and administrative expenses	144,764	148,167	3,403	
Operating income	59,565	63,556	3,991	
Non-operating income	4,220	4,789	569	
Interest income	381	376	(5)	
Dividends income	1,691	1,690	(1)	
Foreign exchange gains	1,377	1,662	285	
Other	770	1,059	289	
Non-operating expenses	4,863	4,439	(424)	
Interest expenses	1,123	888	(235)	
Contribution	1,363	1,413	50	Change in classification from Selling, general and administrative expenses to Non-operating expenses
Litigation expenses	716	1,235	519	
Other	1,660	902	(758)	
Ordinary income	58,922	63,906	4,984	
Extraordinary income	41,680	4,757	(36,923)	
Gain on sales of non-current assets	228	4,203	3,975	FY2013: Sales of rental properties etc. FY2012: Sales of land
Gain on sales of investment securities	1,018	554	(464)	
Gain on exchange of investment securities	40,433	-	(40,433)	FY2013 Shionogi: Construction in process and buildings etc. FY2012 Shionogi Inc.: Goodwill and sales rights etc.
Extraordinary loss	42,296	3,794	(38,502)	
Impairment loss	40,835	878	(39,957)	
Business structure improvement expenses	-	840	840	Due to reorganization of Shionogi Inc. operations etc.
Settlement package	489	651	162	
Loss on penalty	158	500	342	Shionogi: The removal cost of unused assets in Aburahi Facilities
Loss on disposal of non-current assets	-	471	471	
Loss on valuation of Inventories	-	451	451	In connection with acquisition of global rights for Doripenem
Loss on sales of non-current assets	329	-	(329)	
Loss on disaster	269	-	(269)	
Loss on valuation of investment securities	124	-	(124)	
Special retirement expenses	89	-	(89)	
Income before income taxes and minority interests	58,306	64,869	6,563	
Income taxes-current	763	11,561	10,798	FY2012: Due to decrease in Shionogi's income taxes because of loss on valuation of Shionogi Inc.'s stocks (The loss is eliminated upon consolidation.)
Income taxes-deferred	(9,295)	11,375	20,670	
Income before minority interests	66,838	41,932	(24,906)	
Minority interests in income	110	101	(9)	
Net income	66,727	41,831	(24,896)	

The Company has changed its presentation method for litigation expenses from FY2013.

Selling, general and administrative expenses, Operating income and Non-operating expenses for FY2012 has been restated to reflect this change.

8-1. Consolidated balance sheets (Assets)

(Unites: Million yen)

	As of Mar. 31 2013	As of Mar. 31 2014	Change	
(Assets)				
Current assets				
Cash and deposits	21,575	34,238	12,663	
Notes and accounts receivable-trade	67,908	64,290	(3,618)	
Short-term investment securities	84,432	80,100	(4,332)	
Merchandise and finished goods	26,531	24,005	(2,526)	
Work in process	14,024	11,425	(2,599)	
Raw materials and supplies	8,771	12,938	4,167	
Other	43,612	26,154	(17,458)	
Allowance for doubtful accounts	(12)	(24)	(12)	Shionogi: Decrease of income taxes receivable (money received) Decrease of deferred tax assets (Resolution of the loss carried forward)
Total current assets	266,845	253,130	(13,715)	
Non-current assets				
Property, plant and equipment	78,473	78,976	503	
Intangible assets				
Goodwill	40,293	42,878	2,585	Increase /(decrease) by: Amortization (2.7) billion yen Exchange rate fluctuations 4.8 billion yen
Sales rights	24,048	24,355	307	
Other	6,123	5,590	(533)	C&O: Purchase from minority shareholders 0.5 billion yen
Total Intangible assets	70,464	72,824	2,360	
Investments and other assets				
Investment securities	122,628	149,519	26,891	Rise in stock markets
Other	36,560	30,442	(6,118)	
Allowance for doubtful accounts	(90)	(90)	(0)	
Total investments and other assets	159,098	179,871	20,773	
Total non-current assets	308,036	331,673	23,637	
Total assets	574,882	584,803	9,921	

8-2. Consolidated balance sheets (Liabilities/Net Assets)

(Unites: Million yen)

	As of Mar. 31 2013	As of Mar. 31 2014	Change	
(Liabilities)				
Current liabilities				
Notes and accounts payable-trade	10,734	9,627	(1,107)	
Short-term loans payable	7,500	-	(7,500)	Repayment of loans payable
Current portion of long-term loans payable	31,500	-	(31,500)	
Current portion of bonds	-	20,000	20,000	Redemption of 3 rd Series of Shionogi & Co., Ltd. Unsecured Straight bonds
Income taxes payable	1,146	12,392	11,246	FY2012: Shionogi Because of Net loss
Provision for bonuses	7,134	7,071	(63)	
Provision for sales returns	6,459	4,320	(2,139)	
Other provision	26	21	(5)	
Other	33,706	25,236	(8,470)	
Total current liabilities	98,207	78,669	(19,538)	
Non-current liabilities				
Bonds payable	20,000	-	(20,000)	
Long-term loans payable	10,027	10,034	7	
Provision for retirement benefits	8,995	-	(8,995)	Because of changing accounting standard for retirement benefits
Net defined benefit liability	-	9,967	9,967	
Other	14,018	13,719	(299)	
Total non-current liabilities	53,041	33,721	(19,320)	
Total liabilities	151,249	112,390	(38,859)	
(Net Assets)				
Shareholders' equity				
Capital stock	21,279	21,279	-	
Capital surplus	20,227	20,227	-	
Retained earnings	407,007	434,103	27,096	
Treasury stock	(19,741)	(19,756)	(15)	
Total shareholders' equity	428,772	455,854	27,082	
Accumulated other comprehensive income				
Valuation difference on available-for-sale securities	16,055	25,289	9,234	Rising share value
Deferred gains or losses on hedges	(450)	-	450	
Foreign currency translation adjustment	(24,267)	(6,113)	18,154	
Remeasurements of defined benefit plans	-	(6,588)	(6,588)	Because of changing accounting standard for retirement benefits
Total Accumulated other comprehensive income	(8,662)	12,587	21,249	
Subscription rights to shares	123	207	84	
Minority interests	3,399	3,762	363	
Total net assets	423,633	472,412	48,779	
Total liabilities and net assets	574,882	584,803	9,921	

9-1. Quarterly trend for FY2012 and FY2013 (Sales of main merchandise and finished goods)

Fiscal year ended March 31, 2013

(Billions of yen)

FY2012	FY2012 1Q actual	Y on Y change %	FY2012 2Q actual	Y on Y change %	FY2012 3Q actual	Y on Y change %	FY2012 4Q actual	Y on Y change %
Prescription drugs	39.7	0.8	40.0	1.6	45.2	(1.3)	40.8	2.6
CRESTOR	8.6	2.7	10.0	13.3	9.8	4.1	9.7	6.4
IRBETAN Franchise	2.3	9.3	2.4	12.2	3.6	42.4	2.4	12.7
CYMBALTA	2.2	65.5	2.5	62.8	2.4	29.2	2.6	36.4
Total of 3 key products	13.1	11.0	14.9	19.1	15.8	14.4	14.7	11.8
OXYCONTIN Franchise	2.6	16.6	2.5	9.3	2.9	14.2	2.2	19.9
FINIBAX	1.2	23.4	1.2	(2.6)	1.5	6.3	1.1	3.5
DIFFERIN	0.9	8.4	1.0	18.4	1.1	10.0	1.0	3.0
PIRESPA	1.1	34.6	1.2	51.9	1.1	9.5	1.1	43.9
RAPIACTA	0.1	76.2	0.0	-	0.3	49.9	1.6	42.7
Total of 8 strategic products	18.9	13.6	20.9	18.1	22.8	13.8	21.6	14.8
FLOMOX	4.4	(13.7)	4.0	(14.6)	5.4	(9.6)	4.2	(15.1)
RINDERON	2.4	0.9	2.3	(4.8)	2.3	(6.2)	1.9	(3.3)
CLARITIN	1.3	(28.0)	0.9	(32.5)	1.3	(43.0)	2.8	17.0
FLUMARIN	1.5	(14.8)	1.7	(2.7)	1.5	(7.2)	1.3	(29.7)
Export/Overseas subsidiaries	* 7.4	71.4	7.4	-	6.6	(15.1)	9.2	29.0
Shionogi Inc.	3.5	35.4	4.0	-	4.2	2.5	5.3	26.1
C&O	1.5	-	1.4	-	1.3	40.1	1.6	58.4
Contract manufacturing	2.3	39.7	2.2	(0.4)	1.3	(35.2)	1.5	(16.3)
OTC and quasi-drugs	1.3	4.9	1.5	2.4	1.2	(4.8)	1.2	9.9
Diagnostics	0.6	(20.6)	0.5	(16.2)	0.5	(23.8)	0.6	(12.7)
Royalty income	16.0	0.9	17.4	(5.8)	18.8	12.2	17.6	0.4
CRESTOR	14.7	(3.5)	16.0	(6.4)	15.7	(2.0)	16.6	1.0
Others	0.5	(1.3)	0.5	21.6	0.6	10.4	0.6	(0.3)
Total	67.8	6.4	69.5	15.3	74.1	(0.8)	71.5	4.3

Fiscal year ended March 31, 2014

FY2013	FY2013 1Q actual	Y on Y change %	FY2013 2Q actual	Y on Y change %	FY2013 3Q actual	Y on Y change %	FY2013 4Q actual	Y on Y change %
Prescription drugs	40.4	1.9	40.5	1.1	46.5	2.9	40.9	0.2
CRESTOR	10.0	16.7	10.6	5.4	10.6	7.9	9.9	2.5
IRBETAN Franchise	2.9	23.7	3.8	58.2	3.9	9.6	3.3	35.1
CYMBALTA	2.6	19.4	2.6	6.8	3.1	28.3	3.1	17.1
Total of 3 key products	15.5	18.4	17.0	14.1	17.6	11.4	16.2	10.5
OXYCONTIN Franchise	2.7	5.9	2.7	5.4	3.1	6.4	2.1	(0.5)
FINIBAX	1.1	(7.1)	1.2	(3.4)	1.3	(12.2)	1.1	(2.1)
DIFFERIN	0.9	7.2	1.0	(9.4)	1.2	11.1	1.3	30.1
PIRESPA	1.2	15.1	1.2	(10.8)	1.4	26.8	1.0	(1.1)
RAPIACTA	0.1	36.0	0.0	(83.4)	0.4	8.1	1.5	(1.9)
Total of 8 strategic products	21.6	14.4	22.8	9.4	25.1	9.8	23.4	8.1
FLOMOX	3.9	(11.9)	3.6	(11.0)	4.6	(14.0)	3.7	(10.8)
RINDERON	2.4	(0.4)	2.3	(2.3)	2.2	(1.6)	1.9	2.0
CLARITIN	0.9	(26.0)	0.9	(9.4)	1.2	(10.6)	1.9	(31.6)
FLUMARIN	1.4	(7.9)	1.4	(17.4)	1.5	(1.5)	1.1	(12.2)
Export/Overseas subsidiaries	8.4	13.3	7.0	(5.8)	12.0	82.4	6.6	(27.5)
Shionogi Inc.	5.4	53.0	4.1	4.9	8.3	96.0	3.6	(32.9)
Osphena	-	-	0.1	-	0.4	-	0.6	-
C&O	1.3	(14.2)	1.6	13.5	1.3	2.7	1.7	2.8
Contract manufacturing	2.4	1.4	2.6	24.6	0.8	(41.8)	2.6	76.8
OTC and quasi-drugs	1.0	(25.2)	1.3	(9.6)	1.1	(8.3)	1.1	(6.2)
Diagnostics	0.4	(22.6)	0.4	(34.7)	0.5	(6.8)	0.7	25.3
Royalty income	14.0	(12.5)	19.4	11.6	18.1	(3.6)	19.2	8.5
CRESTOR	13.1	(10.9)	18.1	13.1	16.7	6.0	17.8	7.7
Others	0.6	33.2	0.3	(46.2)	0.5	(13.8)	0.4	(13.9)
Total	67.3	(0.8)	71.4	2.8	79.4	7.1	71.6	0.2

Note: Sales of each product are shown on non-consolidated basis

* Because of changing fiscal term, FY2012 1Q actual of Taiwan Shionogi & Co., Ltd. includes 6-month sales from January to June 2012.

9-2. Quarterly trend for FY2012 and FY2013 (Consolidated statements of income)

Fiscal year ended March 31, 2013

(Billions of yen)

FY2012	FY2012 1Q actual *	Y on Y change %	FY2012 2Q actual	Y on Y change %	FY2012 3Q actual	Y on Y change %	FY2012 4Q actual	Y on Y change %
Net sales	67.8	6.4	69.5	15.3	74.1	(0.8)	71.5	4.3
Cost of sales	30.3 20.6	14.0	28.3 19.6	0.8	26.4 19.6	(11.2)	26.2 18.8	3.4
Gross profit	47.2	3.4	49.9	22.2	54.5	3.6	52.7	4.6
SG & A expenses	51.4 34.9	—	51.5 35.8	—	50.3 37.3	—	51.5 36.8	—
Selling & general expenses	23.1	—	22.6	—	22.6	—	23.5	—
R & D expenses	11.8	(10.0)	13.2	4.6	14.7	16.5	13.3	(12.6)
Operating income	18.2	—	20.2	—	23.3	—	22.2	—
Non-operating income & expenses	(0.3)		(1.0)		0.2		0.5	
Ordinary income	17.8	3.2	18.7	93.4	23.6	8.4	22.9	41.7
Extraordinary income & loss	(0.4)		0.1		2.6		(2.9)	
Income before income taxes and minority interests	11.7		13.1		20.1		13.4	
Income taxes and minority interests	4.7		5.2		6.6		(25.0)	
Net income	10.2	82.8	11.4	79.8	18.2	29.9	53.7	350.2

Fiscal year ended March 31, 2014

FY2013	FY2013 1Q actual	Y on Y change %	FY2013 2Q actual	Y on Y change %	FY2013 3Q actual	Y on Y change %	FY2013 4Q actual	Y on Y change %
Net sales	67.3	(0.8)	71.4	2.8	79.4	7.1	71.6	0.2
Cost of sales	27.3 18.4	(10.8)	26.4 18.9	(3.8)	25.4 20.2	3.0	28.7 20.6	9.6
Gross profit	48.9	3.5	52.6	5.4	59.2	8.6	51.1	(3.1)
SG & A expenses	54.6 36.8	5.4	50.7 36.3	1.3	46.8 37.1	(0.3)	53.1 38.0	3.3
Selling & general expenses	23.6	2.2	23.8	5.4	24.8	9.9	24.0	2.4
R & D expenses	13.1	11.6	12.5	(5.8)	12.4	(15.9)	14.0	4.8
Operating income	18.1	(1.7)	22.8	16.0	27.8	27.8	18.2	(17.9)
Non-operating income & expenses	0.5		(1.1)		1.8		(0.8)	
Ordinary income	18.8	4.6	21.3	16.7	30.1	36.6	17.0	(25.4)
Extraordinary income & loss	0.6		3.8		-		(3.3)	
Income before income taxes and minority interests	13.2		19.0		23.9		8.9	
Income taxes and minority interests	2.3		8.4		8.1		4.3	
Net income	16.1	56.9	14.8	32.8	19.9	17.5	6.4	(88.0)

* Because of changing fiscal term, FY2012 1Q actual of Taiwan Shionogi & Co., Ltd. includes 6-month results from January to June 2012.

The Company has changed its presentation method for litigation expenses from the first quarter of the fiscal year ended March 31, 2014.

SG & A expenses, Selling & general expenses, Operating income and Non-operating income & expenses for the fiscal year ended March 31, 2013 has been restated to reflect this change.

However, the Y on Y change % has been omitted because it has not been calculated.

10. Consolidated affiliated companies and affiliated company accounted for by the equity method

<Consolidated affiliated companies and affiliated companies accounted for by the equity method>

No	Company name	Location	Common stock	Business status	Establish	Closing date	Ownership (%)
1	Shionogi Pharma Chemicals Co., Ltd.	Tokushima, Japan	JPY 200 million	Mfg. of pharmaceutical raw materials	August 24, 1976	March 31	100
2	Saishin Igaku Co., Ltd.	Osaka, Japan	JPY 90 million	Publication of medical information	December 21, 1998	March 31	100
3	Shionogi General Service Co., Ltd.	Osaka, Japan	JPY 10 million	Real estate rental, Insurance agency and contract general services	November 2, 1992	March 31	100
4	Shionogi Analysis Center Co., Ltd.	Osaka, Japan	JPY 200 million	Contract testing and analysis on medicine	December 21, 2007	March 31	100
5	Aburahi AgroResearch Co., Ltd.	Shiga, Japan	JPY 10 million	Contract Laboratories for agro chemicals	February 26, 2004	March 31	* 100
6	Shionogi Techno Advance Research Co., Ltd.	Osaka, Japan	JPY 9 million	Contract support services for experimental research	September 8, 2010	March 31	100
7	Taiwan Shionogi & Co., Ltd.	Taipei, Taiwan, R.O.C.	TWD 92 million	Mfg. and sale of pharmaceuticals	December 26, 1963	March 31	100
8	Shionogi Inc.	Delaware, U.S.A.	USD 8	Mfg. and sale of pharmaceuticals	August 25, 2008	March 31	100
9	SG Holding, Inc.	Delaware, U.S.A.	USD 140	Holding company	September 10, 2001	March 31	* 100
10	Ezose Sciences Inc.	Delaware, U.S.A.	USD 15	Serum glycan analysis contract services	March 3, 2009	March 31	* 100
11	C&O Pharmaceutical Technology (Holdings) Limited	Bermuda Islands	HKD 165,840 thousand	Mfg. and sale of pharmaceuticals	July 28, 2003	December 31	71
12	Shionogi Ltd.	London, U.K.	GBP 700 thousand	Contract research for pharmaceuticals	February 10, 2012	March 31	100
13	Beijing Shionogi Pharmaceutical Technology Limited	Beijing, China	JPY 30 million	Support services for development and sales	March 29, 2013	December 31	100
14	Shionogi Singapore Pte. Ltd.	Singapore	SGD 400 thousand	Development and sales	December 30, 2013	March 31	100

* Incl. Indirect ownership

Note: Twenty-three consolidated affiliated companies and three affiliated companies accounted for by the equity method are not shown on this table as the scale of their business is very small.

11. Pipeline (as of May 2014)

Areas	Code No. (Generic name) 【Product name】	Category (Administration)	Indication	Stage	Origin	Development
Infectious Diseases	S-649266	Cephem antibiotic (Injection)	Infection	Japan: Phase I USA: Phase II	In-house	In-house
Metabolic Syndrome	S-556971	Cholesterol absorption inhibitor (Oral)	Dyslipidemia	Japan: Phase II	Kotobuki Pharmaceutical Co., Ltd. (Japan)	Shionogi/Kotobuki Pharmaceutical Co., Ltd.
	S-707106	Insulin sensitizer (Oral)	Type 2 diabetes	USA: Phase IIa	In-house	In-house
	S-237648	Neuropeptide Y Y5 receptor antagonist (Oral)	Obesity	Japan: Phase I	In-house	In-house
Pain	LY248686 Duloxetine hydrochloride 【Cymbalta®】	SNRI (Serotonin & noradrenaline reuptake inhibitor) (Oral)	Chronic low back pain	Japan: Phase III	Eli Lilly (USA)	Shionogi/Eli Lilly Japan K.K.
	S-297995 (Naldemedine)	Peripheral opioid receptor antagonist (Oral)	Alleviation of opioid-induced adverse effects	Global: Phase III Japan: Phase III	In-house	In-house
	S-117957	Analgesic agent for neuropathic pain (Oral)	Neuropathic pain	USA: POM (Proof of Mechanism)	Shionogi/Purdue Pharma L.P. (USA)	Shionogi/Purdue Pharma L.P.
	S-120083	Analgesic agent for inflammatory pain (Oral)	Inflammatory pain	Japan: Phase I	Shionogi/Purdue Pharma L.P. (USA)	Shionogi/Purdue Pharma L.P.
	S-010887	Analgesic agent for neuropathic pain (Oral)	Neuropathic pain	Japan: Phase I	In-house	In-house
Other	Ospemifene	Selective estrogen receptor modulator (Oral)	Post-menopausal vaginal atrophy	USA: Approval (Feb. 2013) Europe: NDA submission (Mar. 2013)	QuatRx Pharmaceuticals Company (USA)	Shionogi/QuatRx Pharmaceuticals Company
	S-524101	Sublingual tablet of house-dust mite allergen extracts for immunotherapy	Allergic rhinitis caused by house-dust mite allergen	Japan: NDA submission (Apr. 2014)	Stallergenes SA (France)	In-house
	S-555739	Prostaglandin D2 receptor antagonist (Oral)	Allergic rhinitis	Japan: Phase III USA: Phase IIa Europe: POM (Proof of Mechanism)	In-house	In-house
	S-888711 (Lusutrombopag)	Small molecule TPO mimetic (Oral)	Thrombocytopenia	USA, Europe: Phase II Japan: Phase III	In-house	In-house
	S-877503 (Guanfacine hydrochloride)	Alpha-2A-adrenergic receptor agonist (Oral)	ADHD	Japan: Phase II/III	Shire (Ireland)	Shionogi/Shire
	S-877489 (Lisdexamfetamine)	DA and NE reuptake inhibitor/Releaser of DA, NE (Oral)	ADHD	Japan: Phase II	Shire (Ireland)	Shionogi/Shire
	S-588410	Cancer peptide vaccine (Injection)	Bladder cancer	Japan, Europe: Phase II	OncoTherapy Science, Inc. (Japan)	In-house
	S-488210	Cancer peptide vaccine (Injection)	Head and neck squamous cell carcinoma	Europe: Phase I/II	OncoTherapy Science, Inc. (Japan)	In-house
	S-646240	Peptide vaccine (Injection)	Age-related macular degeneration	Japan: Phase IIa	OncoTherapy Science, Inc. (Japan)	In-house
	S-222611	HER2/EGFR dual inhibitor (Oral)	Malignant tumor	Europe: Phase I/II	In-house	In-house
S-525606	Sublingual tablet of Japanese cedar allergen extracts for immunotherapy	Allergic rhinitis caused by Japanese cedar allergen	Japan: Phase I (in preparation)	Stallergenes SA (France)	In-house	

<Out-Licensing Activity>

Code No. (Generic name)	Category (Administration)	Indication	Stage	Origin	Development
S/GSK1349572 (Dolutegravir)	Integrase inhibitor (Oral)	HIV infection	Global: NDA submission (Dec. 2012) USA: Approval (Aug. 2013) Europe: Approval (Jan. 2014) Japan: Approval (Mar. 2014) Other: Approval in 5 countries	Shionogi-ViiV Healthcare LLC	ViiV Healthcare Ltd. (UK)
Dolutegravir/Abacavir/Lamivudine	Integrase inhibitor/Nucleoside reverse transcriptase inhibitor (Oral)	HIV infection	USA, Europe: NDA submission (Oct. 2013)	Shionogi-ViiV Healthcare LLC	ViiV Healthcare Ltd. (UK)
S/GSK1265744 LAP*	Integrase inhibitor (Injection)	HIV infection	USA: Phase II	Shionogi-ViiV Healthcare LLC	ViiV Healthcare Ltd. (UK)
S-0373	Non-peptide mimetic of TRH (Oral)	Spinocerebellar ataxia	Japan: Phase III	In-house	Kissei Pharmaceutical Co., Ltd. (Japan)
Janssen/Shionogi BACE inhibitor	BACE inhibitor (Oral)	Alzheimer's disease	Europe: Phase I	In-house	Janssen Pharmaceuticals, Inc. (USA)

*: Long acting parenteral formulation

<Drugs to acquire new indication requested by the Ministry of Health, Labour and Welfare>

Generic name 【Product name】	Category (Administration)	Indication	Stage	Origin	Development
Oxycodone hydrochloride hydrate 【OxyContin®】	Natural opium alkaloids (Oral)	For the treatment of moderate to severe chronic pain	Japan: Phase III	Napp Pharmaceuticals Limited (UK)	In-house
Duloxetine hydrochloride 【Cymbalta®】	SNRI (Serotonin & noradrenaline reuptake inhibitor) (Oral)	Fibromyalgia	Japan: NDA submission (in preparation)	Eli Lilly (USA)	Shionogi/Eli Lilly Japan K.K.
Vancomycin hydrochloride 【Vancomycin】	Glycopeptide antibiotic (Drip infusion)	1. <Spectrum> Vancomycin-sensitive Methicillin resistant coagulase negative Staphylococcus (MRCNS) <Indication> Septicemia, Infectious endocarditis, (Superficial) Secondary infections in trauma, Burns, Surgical wounds, etc., Osteomyelitis, Arthritis, Peritonitis, Bacterial meningitis 2. Febrile Neutropenia suspected of MRSA or MRCNS infection	Japan: NDA submission (Nov. 2013)	Eli Lilly (USA)	In-house

<Requested for development by academy>

Generic name 【Product name】	Category (Administration)	Indication	Stage	Origin	Development
Interferon gamma-1a 【Imunomax®-γ】	Interferon gamma-1a (Genetical recombination) (Injection)	Mycosis fungoides/Sezary syndrome	Japan: NDA submission (Aug. 2013)	Biogen Idec, Inc. (USA)	In-house

Since February 2014

Change of phase	S-649266: USA: Phase I → USA: Phase II
	S-524101: Japan: NDA submission (in preparation) → Japan: NDA submission (Apr. 2014)
	S/GSK1349572 (Dolutegravir): Japan: NDA submission (Dec. 2013) → Japan: Approval (Mar. 2014)
	Duloxetine hydrochloride 【Cymbalta®】 Fibromyalgia: Japan: Phase III → Japan: NDA submission (in preparation)
Compound added to the list	S-525606: Japan: Phase I (in preparation)
Compound erased from the list	S-234462: Japan: Closed (Mar. 2014)
	S-414114: For the main constituent of the development moved to AnGes MG, Inc. (May 2014)